Webinar 17/06/24, page-22

the neurosurgeons need to be qualified to administer car t cell therapies (in our case dual intraventicular administration). Now given that car T cells have historically only been used for treating blood cancers, then it follows that neurosurgeons would not be experts in car T.

importantly, there are a number of existing oncology therapies that involve intraventricular administration into the brain (to overcome the blood brain barrier).

furthermore, given a successful car t treatment for glioblastoma would cost patients up to USD1m I don’t see why big pharma couldn’t train the relevant specialist. I mean the throw money at them for conferences etc